{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:50:29Z","timestamp":1781103029541,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.trre.2020.100587","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T18:08:17Z","timestamp":1604340497000},"page":"100587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Antiviral treatment approaches for cytomegalovirus prevention in kidney transplant recipients: A systematic review of randomized controlled trials"],"prefix":"10.1016","volume":"35","author":[{"given":"Amit D.","family":"Raval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Kistler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Snydman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2020.100587_bb0005","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/652438","article-title":"Cytomegalovirus Seroprevalence in the United States: the National Health and nutrition examination surveys, 1988\u20132004","volume":"50","author":"Bate","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2020.100587_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.trre.2020.100587_bb0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.23876\/j.krcp.18.0063","article-title":"Common viral infections in kidney transplant recipients","volume":"37","author":"Vanichanan","year":"2018","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.trre.2020.100587_bb0020","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the Management of Cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2020.100587_bb0025","article-title":"Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients","volume":"2","author":"Owers","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.trre.2020.100587_bb0030","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","author":"Hodson","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.trre.2020.100587_bb0035","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/cit945","article-title":"A direct and indirect comparison meta-analysis on the efficacy of Cytomegalovirus preventive strategies in solid organ transplant","volume":"58","author":"Florescu","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2020.100587_bb0055","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.transproceed.2018.01.023","article-title":"Effect of low-dose vs standard-dose Valganciclovir in the prevention of Cytomegalovirus disease in kidney transplantation recipients: a systemic review and meta-analysis","volume":"50","author":"Hwang","year":"2018","journal-title":"Transplant Proc"},{"issue":"7","key":"10.1016\/j.trre.2020.100587_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.trre.2020.100587_bb0065","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3947\/ic.2013.45.3.260","article-title":"Cytomegalovirus infections in solid organ transplantation: a review","volume":"45","author":"Ramanan","year":"2013","journal-title":"Infect Chemother"},{"key":"10.1016\/j.trre.2020.100587_bb0070","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1600-6143.2011.03766.x","article-title":"High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy","volume":"12","author":"Couzi","year":"2012","journal-title":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"key":"10.1016\/j.trre.2020.100587_bb0075","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00044011-200019050-00007","article-title":"A 3-year follow-up of pre-emptive vs deferred treatment of cytomegalovirus disease in renal transplantation","volume":"19","author":"Shnitzler","year":"2000","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.trre.2020.100587_bb0080","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1681\/ASN.V81118","article-title":"Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy","volume":"8","author":"Brennan","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2020.100587_bb0085","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1432-2277.2002.tb00120.x","article-title":"A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation","volume":"15","author":"Reischig","year":"2002","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2020.100587_bb0090","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3851\/IMP3129","article-title":"The impact of viral load and time to onset of cytomegalovirus replication on long-term graft survival after kidney transplantation","volume":"22","author":"Reischig","year":"2017","journal-title":"Antivir Ther"},{"key":"10.1016\/j.trre.2020.100587_bb0095","doi-asserted-by":"crossref","DOI":"10.3851\/IMP1485","article-title":"Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients","volume":"15","author":"Reischig","year":"2010","journal-title":"Antiviral therapy"},{"key":"10.1016\/j.trre.2020.100587_bb0100","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1681\/ASN.2012010100","article-title":"Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation","volume":"23","author":"Reischig","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2020.100587_bb0105","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2215\/CJN.07020714","article-title":"Randomized trial of Valganciclovir versus Valacyclovir prophylaxis for prevention of Cytomegalovirus in renal transplantation","volume":"10","author":"Reischig","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2020.100587_bb0110","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.TP.0000150024.01672.CA","article-title":"Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection","volume":"79","author":"Reischig","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2020.100587_bb0115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-6143.2007.02031.x","article-title":"Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation","volume":"8","author":"Reischig","year":"2008","journal-title":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"key":"10.1016\/j.trre.2020.100587_bb0120","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3851\/IMP1879","article-title":"Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients","volume":"16","author":"Reischig","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.trre.2020.100587_bb0125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000013379","article-title":"Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay","volume":"18","author":"Yang","year":"1998","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.trre.2020.100587_bb0130","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1469-0691.2005.01215.x","article-title":"A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients","volume":"11","author":"Pavlopoulou","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trre.2020.100587_bb0135","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.1111\/j.1432-2277.1994.tb01384.x","article-title":"Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients","volume":"7","author":"Rostaing","year":"1994","journal-title":"Transplant international\u202f: official journal of the European Society for Organ Transplantation"},{"key":"10.1016\/j.trre.2020.100587_bb0140","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"key":"10.1016\/j.trre.2020.100587_bb0145","first-page":"526","article-title":"Efficacy and safety of low-dose versus standard-dose Valganciclovir for prevention of Cytomegalovirus disease in intermediate-risk kidney transplant recipients","volume":"14","author":"Halim","year":"2016","journal-title":"Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation"},{"key":"10.1016\/j.trre.2020.100587_bb0150","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1399-0012.1997.tb01057.x","article-title":"Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients","volume":"11","author":"Ahsan","year":"1997","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2020.100587_bb0155","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in D+\/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2020.100587_bb0160","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1681\/ASN.V72325","article-title":"Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients","volume":"7","author":"Kletzmayr","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2020.100587_bb0165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/TP.0b013e3181e81afc","article-title":"Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes","volume":"90","author":"Spinner","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2020.100587_bb0170","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1600-6143.2007.02133.x","article-title":"Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial","volume":"8","author":"Kliem","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2020.100587_bb0175","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.transproceed.2007.03.046","article-title":"Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients","volume":"39","author":"Said","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2020.100587_bb0180","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1159\/000335962","article-title":"Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients","volume":"35","author":"Kielberger","year":"2012","journal-title":"Kidney and Blood Pressure Research"},{"key":"10.1016\/j.trre.2020.100587_bb0185","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1128\/AAC.35.5.938","article-title":"Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients","volume":"35","author":"Fletcher","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2020.100587_bb0190","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/archsurg.1995.01430110075014","article-title":"Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients","volume":"130","author":"Conti","year":"1995","journal-title":"archives of surgery (Chicago, Ill. : 1960)"},{"key":"10.1016\/j.trre.2020.100587_bb0195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/0003-4819-123-1-199507010-00002","article-title":"Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial","volume":"123","author":"Hibberd","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2020.100587_bb0200","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1016\/S0041-1345(01)02558-1","article-title":"Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation","volume":"33","author":"Jung","year":"2001","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2020.100587_bb0205","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/j.1600-6143.2006.01413.x","article-title":"Prophylactic versus preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in adult renal transplant recipients","volume":"6","author":"Khoury","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2020.100587_bb0210","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1111\/tri.1992.5.s1.30","article-title":"Prophylaxis of CMV disease by ganciclovir (DHPG) in seronegative recipients of renal allograft from seropositive donors","volume":"5","author":"Rondeau","year":"1992","journal-title":"Transplant international: official journal of the European Society for Organ Transplantation"},{"key":"10.1016\/j.trre.2020.100587_bb0215","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/archsurg.1994.01420280121016","article-title":"Prophylaxis of primary cytomegalovirus disease in renal transplant recipients: a trial of ganciclovir vs immunoglobulin","volume":"129","author":"Conti","year":"1994","journal-title":"Arch Surg"},{"key":"10.1016\/j.trre.2020.100587_bb0220","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0041-1345(96)00143-1","article-title":"Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients","volume":"29","author":"Brennan","year":"1997","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2020.100587_bb0225","first-page":"459","article-title":"Randomized case-controlled trial of oral low-dose acyclovir for prevention of virus infections in recipients of renal allografts","volume":"108","author":"Jiang","year":"1995","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.trre.2020.100587_bb0230","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1097\/00007890-199812270-00019","article-title":"A randomized prospective controlled trial of oral acyclovir versus oral, ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"66","author":"Flechner","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2020.100587_bb0235","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.transproceed.2005.08.007","article-title":"A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients","volume":"37","author":"Nafar","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2020.100587_bb0240","first-page":"156","article-title":"Successful cost-effective prevention of cytomegalovirus disease in kidney transplant recipients using low-dose valganciclovir","volume":"15","author":"Gheith","year":"2017","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.trre.2020.100587_bb0245","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJM199905133401903","article-title":"Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus prophylaxis transplantation study group","volume":"340","author":"Lowance","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2020.100587_bb0250","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/TP.0000000000002024","article-title":"Valganciclovir prophylaxis versus preemptive therapy in Cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized clinical trial","volume":"102","author":"Witzke","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2020.100587_bb0255","series-title":"Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients","author":"Brennan","year":"1997"},{"key":"10.1016\/j.trre.2020.100587_bb0260","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/TP.0b013e318238dab3","article-title":"Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial","volume":"93","author":"Witzke","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2020.100587_bb0265","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-6143.2010.03342.x","article-title":"IMPACT trial results should not change current standard of care of 100 days for cytomegalovirus prophylaxis","volume":"11","author":"Kalil","year":"2011","journal-title":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"key":"10.1016\/j.trre.2020.100587_bb0270","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJM198905253202105","article-title":"A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts","volume":"320","author":"Balfour","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2020.100587_bb0275","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1093\/ndt\/gfg302","article-title":"Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study","volume":"18","author":"Sagedal","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.trre.2020.100587_bb0280","first-page":"2448","article-title":"Prophylactic treatment of cytomegalovirus primary infection with ganciclovir in renal transplant recipients","volume":"27","author":"Leray","year":"1995","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2020.100587_bb0285","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1399-3062.2000.020303.x","article-title":"Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis","volume":"2","author":"Rubin","year":"2000","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2020.100587_bb0290","first-page":"858","article-title":"Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients","volume":"8","author":"Rondeau","year":"1993","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.trre.2020.100587_bb0295","first-page":"2811","article-title":"Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial","volume":"28","author":"Pouteil-Noble","year":"1996","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2020.100587_bb0305","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1097\/00007890-199806270-00758","article-title":"A randomized prospective controlled trial of oral acyclovir versus oral, ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients (abstract)","volume":"65","author":"Flechner","year":"1998","journal-title":"Transplantation"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X20300604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X20300604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T16:05:47Z","timestamp":1760630747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X20300604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0955470X20300604"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2020.100587","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral treatment approaches for cytomegalovirus prevention in kidney transplant recipients: A systematic review of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2020.100587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100587"}}